Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Feb. 28, 2018	Apr. 06, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Trading Symbol	ORMP
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Document Type	10-Q
Document Period End Date	Feb. 28, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		14,442,683

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Feb. 28, 2018	Aug. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 3,295	$ 3,969
Short-term deposits	14,379	13,293
Marketable securities	3,229	2,860
Restricted cash		16
Prepaid expenses and other current assets	224	159
Total current assets	21,127	20,297
LONG-TERM ASSETS:
Long-term deposits and investment	13,788	16,232
Marketable securities	3,306	2,151
Amounts funded in respect of employee rights upon retirement	15	14
Property and equipment, net	18	18
Total long-term assets	17,127	18,415
Total assets	38,254	38,712
CURRENT LIABILITIES:
Accounts payable and accrued expenses	2,156	2,716
Deferred revenues	2,449	2,449
Payable to related parties	113
Total current liabilities	4,718	5,165
LONG-TERM LIABILITIES:
Deferred revenues	12,622	13,837
Employee rights upon retirement	19	18
Provision for uncertain tax position	11	11
Other liabilities	404	443
Total long-term liabilities	13,056	14,309
COMMITMENTS (note 2)
STOCKHOLDERS' EQUITY:
Common stock, $0.012 par value (30,000,000 authorized shares; 14,405,892 and 13,668,530 shares issued and outstanding as of February 28, 2018 and August 31, 2017, respectively)	171	163
Additional paid-in capital	81,939	75,170
Accumulated other comprehensive income	313	401
Accumulated loss	(61,943)	(56,496)
Total stockholders' equity	20,480	19,238
Total liabilities and stockholders' equity	$ 38,254	$ 38,712

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Feb. 28, 2018	Aug. 31, 2017
Balance Sheets [Abstract]
Common stock, par value	$ 0.012	$ 0.012
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	14,405,892	13,668,530
Common stock, shares outstanding	14,405,892	13,668,530

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Feb. 28, 2018	Feb. 28, 2017	Feb. 28, 2018	Feb. 28, 2017
Income Statement [Abstract]
REVENUES	$ 604	$ 611	$ 1,215	$ 1,221
COST OF REVENUES				187
RESEARCH AND DEVELOPMENT EXPENSES	2,724	3,125	5,051	5,478
GENERAL AND ADMINISTRATIVE EXPENSES	991	851	2,007	1,319
OPERATING LOSS	3,111	3,365	5,843	5,763
FINANCIAL INCOME	217	203	439	389
FINANCIAL EXPENSES	22	21	43	45
LOSS BEFORE TAXES ON INCOME	2,916	3,183	5,447	5,419
TAXES ON INCOME				400
NET LOSS FOR THE PERIOD	2,916	3,183	5,447	5,819
UNREALIZED LOSS (INCOME) ON AVAILABLE FOR SALE SECURITIES	414	(168)	88	(105)
TOTAL OTHER COMPREHENSIVE LOSS (INCOME)	414	(168)	88	(105)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ 3,330	$ 3,015	$ 5,535	$ 5,714
LOSS PER SHARE OF COMMON STOCK:
BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	$ 0.20	$ 0.24	$ 0.38	$ 0.44
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	14,445,844	13,279,788	14,342,024	13,242,676

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - 6 months ended Feb. 28, 2018 - USD ($)
$ in Thousands

Total

Common Stock

Additional paid-in capital

Accumulated other comprehensive income

Accumulated loss

BALANCE at Aug. 31, 2017

$ 19,238

$ 163

$ 75,170

$ 401

$ (56,496)

BALANCE, Shares at Aug. 31, 2017

13,668

CHANGES DURING THE SIX-MONTH PERIOD ENDED FEBRUARY 28, 2018:

SHARES ISSUED FOR SERVICES

^[1]

SHARES ISSUED FOR SERVICES, Shares

ISSUANCE OF COMMON STOCK, NET

4,881

$ 6

4,875

ISSUANCE OF COMMON STOCK, NET, Shares

533

EXERCISE OF WARRANTS AND OPTIONS

997

$ 2

995

EXERCISE OF WARRANTS AND OPTIONS, Shares

189

STOCK-BASED COMPENSATION

856

^[1]

856

STOCK-BASED COMPENSATION, Shares

NET LOSS

(5,447)

OTHER COMPREHENSIVE LOSS

(88)

BALANCE at Feb. 28, 2018

$ 20,480

$ 171

$ 81,939

$ 313

$ (61,943)

BALANCE, Shares at Feb. 28, 2018

14,406

[1]	Represents an amount of less than $1.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Feb. 28, 2018	Feb. 28, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,447)	$ (5,819)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	3	2
Exchange differences and interest on deposits and held to maturity bonds	106	(57)
Stock-based compensation	856	494
Shares issued for services	43	32
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(65)	47
Accounts payable, accrued expenses and related parties	(447)	1,025
Deferred revenues	(1,215)	2,755
Liability for employee rights upon retirement	1	3
Other liabilities	(39)	91
Total net cash used in operating activities	(6,204)	(1,427)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(3)	(2)
Purchase of short-term deposits	(4,351)	(1,500)
Purchase of long-term deposits	(5,540)	(9,000)
Purchase of held to maturity securities	(2,879)	(2,090)
Proceeds from sale of short-term deposits	11,216	10,344
Proceeds from maturity of held to maturity securities	1,207	900
Funds in respect of employee rights upon retirement	(1)	(1)
Total net cash used in investing activities	(351)	(1,349)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs	4,881
Proceeds from exercise of warrants and options	997	320
Total net cash provided by financing activities	5,878	320
EFFECT OF EXCHANGE RATE CHANGES ON CASH	3	1
DECREASE IN CASH AND CASH EQUIVALENTS	(674)	(2,455)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	3,969	3,907
CASH AND CASH EQUIVALENTS AT END OF PERIOD	3,295	1,452
SUPPLEMENTARY DISCLOSURE ON CASH FLOWS -
Interest received	$ 457	$ 288

Significant Accounting Policies

6 Months Ended

Feb. 28, 2018

Significant Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General:

Incorporation and operations

Oramed Pharmaceuticals Inc. (collectively with its subsidiary, the “Company”, unless the context indicates otherwise) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd. (“Hadasit”) to acquire the provisional patent related to an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

On November 30, 2015, the Company entered into a Technology License Agreement with Hefei Tianhui Incubation of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “License Agreement”). According to the License Agreement, the Company granted HTIT an exclusive commercialization license in the territory of the People's Republic of China, Macau and Hong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801 (the "Product"). Pursuant to the License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company's patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.

The royalty payment obligation shall apply during the period of time beginning upon the first commercial sale of the Product in the Territory, and ending upon the later of (i) the expiration of the last-to-expire licensed patents in the Territory; and (ii) 15 years after the first commercial sale of the Product in the Territory (the "Royalty Term").

The License Agreement shall remain in effect until the expiration of the Royalty Term. The License Agreement contains customary termination provisions.

Among others, the Company's involvement through the product submission date will include consultancy for the pre-commercialization activities in the Territory, as well as advisory services to HTIT on an ongoing basis.

In addition, on November 30, 2015, the Company entered into a Stock Purchase Agreement with HTIT (the “SPA”). According to the SPA, the Company issued 1,155,367 shares of common stock to HTIT for $12,000. The transaction closed on December 28, 2015.

Amounts that were allocated to the License Agreement as of February 28, 2018 aggregated $19,383, all of which were received through the balance sheet date. Through February 28, 2018, the Company recognized revenue in the amount of $4,312, and deferred the remaining amount of $15,071.

The following table sets forth the transactions in deferred revenues balances for the six-month period ended February 28, 2018 and the year ended August 31, 2017:

	Six months ended February 28,			Year ended August 31,
	2018			2017

Deferred revenue at the beginning of period	$	16,286		$	14,766
Amounts received		-			4,000
Amounts due to the Company		-			(24	)
Revenue recognized		(1,215	)		(2,456	)
Deferred revenue at the end of period		15,071			16,286
Less – current deferred revenue portion		(2,449	)		(2,449	)
Non-current deferred revenue portion	$	12,622		$	13,837

Development and liquidity risks

The Company is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated significant revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable. Successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration prior to selling its products within the United States, obtaining foreign regulatory approvals to sell its products internationally, or entering into licensing agreements with third parties. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.

Loss per common share

Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for each period. Outstanding stock options, warrants and restricted stock units (“RSUs”) have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The weighted average number of common stock options, warrants and RSUs excluded from the calculation of diluted net loss was 1,406,175 and 2,053,153 for the six-month periods ended February 28, 2018 and 2017, respectively, and 1,388,122 and 1,631,174 for the three-month periods ended February 28, 2018 and 2017, respectively.

Condensed Consolidated Financial Statements Preparation

The condensed consolidated financial statements included herein have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and on the same basis as the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2017 (the “2017 Form 10-K”). These condensed consolidated financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results of the periods presented. Certain information and disclosures normally included in annual consolidated financial statements have been omitted in this interim period report pursuant to the rules and regulations of the Securities and Exchange Commission. Because the condensed consolidated interim financial statements do not include all of the information and disclosures required by U.S. GAAP for annual financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in the 2017 Form 10-K. The results for interim periods are not necessarily indicative of a full fiscal year’s results.

Newly issued and recently adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2014-09 (Topic 606) “Revenue from Contracts with Customers” that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle of this ASU is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective in annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company will implement the guidance for the annual period ending on August 31, 2019. The Company is currently evaluating the impact of the guidance on its consolidated financial statements.

In January 2016, the FASB issued guidance on recognition and measurement of financial assets and financial liabilities (ASU No. 2016-01) that will supersede most current guidance. Changes to the U.S. GAAP model primarily affect the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities, is largely unchanged. The classification and measurement guidance will be effective September 1, 2018. The Company is currently evaluating the impact of the guidance on its consolidated financial statements.

Commitments

6 Months Ended

Feb. 28, 2018

Commitments [Abstract]

COMMITMENTS

NOTE 2 - COMMITMENTS:

In March 2011, the Subsidiary sold shares of its investee company, Entera Bio Ltd. (“Entera”) to D.N.A Biomedical Solutions Ltd. (“D.N.A”), retaining a 3% interest as of March 2011, which is accounted for as a cost method investment (amounting to $1). In consideration for the shares sold to D.N.A, the Company received, among other payments, 4,202,334 ordinary shares of D.N.A (see also note 4).

As part of this agreement, the Subsidiary entered into a patent transfer agreement according to which the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera’s net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of February 28, 2018, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary.

In addition, as part of a consulting agreement with a third party, dated February 15, 2011, the Subsidiary is obliged to pay this third party royalties of 8% of the net royalties received in respect of the patent that was sold to Entera in March 2011.

On January 3, 2017, the Subsidiary entered into a lease agreement for its office facilities in Israel. The lease agreement is for a period of 60 months commencing October 1, 2016.

The annual lease payment is New Israeli Shekel (“NIS”) 119,000 ($34) from October 2016 through September 2018 and NIS 132,000 ($38) from October 2018 through September 2021, and is linked to the increase in the Israeli consumer price index (“CPI”) (as of February 28, 2018, the future lease payments until the expiration of the lease agreement will be $134, based on the exchange rate as of February 28, 2018).

As security for its obligation under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease payments.

On March 3, 2016, the Subsidiary entered into an agreement with a vendor for process development and production of its capsules and on November 24, 2016, April 3, 2017 and July 10, 2017 into amendments to such agreement in an amount of up to Swiss Franc (“CHF”) 1,000,000 ($1,061), CHF 665,000 ($675) of which was recognized through February 28, 2018.

On May 11, 2016, the Subsidiary entered into a Master Service Agreement with a vendor to retain its services for a pre-clinical toxicology trial for an oral GLP-1 analog capsule for type 2 diabetes patients. As consideration for its services, the Subsidiary will pay the vendor a total amount of $1,283 during the term of the engagement and based on achievement of certain milestones, of which $1,275 was recognized through February 28, 2018.

On June 13, 2016, the Subsidiary entered into a four-year service agreement with a third party and on December 19, 2016, this agreement and all of the third party rights and obligations thereunder were assigned to another third party. This agreement is required by the License Agreement as described in note 1 and will support the Company's research and development. The Subsidiary is obligated to pay the third party a total amount of up to €2,360,000 ($2,780), of which €1,187,390 ($1,347) was recognized in research and development through February 28, 2018.

On July 24, 2016, the Subsidiary entered into a General Technical Agreement with a vendor for the scale-up process development and production of one of its oral capsule ingredients in the amount of $4,300 that will be paid over the term of the engagement and based on the achievement of certain development milestones, $3,989 of which were recognized in research and development expenses through February 28, 2018. This agreement is part of the requirements of the License Agreement as described in note 1.

On February 21, 2017, the Subsidiary entered into an agreement with a vendor to retain its services for a pre-clinical toxicology trial for an oral insulin capsule for type 2 and type 1 diabetes patients. As consideration for its services, the Subsidiary will pay the vendor a total of up to $952 during the term of the engagement and based on achievement of certain milestones, of which $786 was recognized through February 28, 2018.

On May 3, 2017, the Company entered into a consulting agreement with a third party advisor for a period of one year, pursuant to which such advisor will provide investor relations services and will be entitled to receive a monthly cash fee and 10,000 shares of the Company’s common stock that will be issued in four equal quarterly installments commencing August 1, 2017. As of February 28, 2018, the Company had issued to such advisor 7,500 shares. The fair value of the shares at the grant date was $64.

On June 5, 2017, the Subsidiary entered into a clinical research agreement with a vendor, for the conduct of its clamp clinical trial for an oral insulin capsule for type 1 diabetes patients. As consideration for its services, the Subsidiary will pay the vendor a total amount of $958 during the term of the engagement and based on achievement of certain milestones, $160 of which was recognized through February 28, 2018.

On December 18, 2017, the Subsidiary entered into an agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $2,905 that will be paid over the term of the engagement and based on the achievement of certain development milestones, $109 of which were recognized in research and development expenses through February 28, 2018.

On February 14, 2018, the Subsidiary entered into a Clinical Research Organization Services Agreement with a third party, effective as of November 1, 2017, to retain it as a clinical research organization ("CRO") for the Subsidiary’s three-month dose-ranging clinical trial for its oral insulin capsule for type 2 diabetes patients. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $7,030 during the term of the engagement and based on achievement of certain milestones, $547 of which were recognized through February 28, 2018.

Grants from the Bio-Jerusalem Fund (“Bio-Jerusalem”)

The Subsidiary is committed to pay royalties to Bio-Jerusalem on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received (Israeli CPI linked) at the total amount of $65. The Company received no grants from Bio-Jerusalem since fiscal year 2013.

As of February 28, 2018, the royalty expenses which are related to the funded project were recognized in cost of revenues in prior periods.

Grants from the Israel Innovation Authority ("IIA")

Under the terms of the Company’s funding from the IIA, royalties of 3.5% are payable on sales of products developed from a project so funded, up to a maximum amount equaling 100%-150% of the grants received (dollar linked) with the addition of interest at an annual rate based on LIBOR.

At the time the grants were received, successful development of the related projects was not assured.

The total amount that was received through February 28, 2018 was $2,194.

As of February 28, 2018, the royalty expenses which are related to the funded project were recognized in cost of revenues in prior periods.

Fair Value

6 Months Ended

Feb. 28, 2018

Fair Value [Abstract]

FAIR VALUE

NOTE 3 - FAIR VALUE:

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

	Level 1:	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

	Level 2:	Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

	Level 3:	Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of February 28, 2018, the assets or liabilities measured at fair value are comprised of available for sale equity securities (Level 1).

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.

As of February 28, 2018, the carrying amount of cash equivalents, short-term deposits and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term maturities of these instruments.

As of February 28, 2018, the carrying amount of long-term deposits approximates their fair values due to the stated interest rates which approximate market rates.

The fair value of held to maturity bonds as presented in note 4 was based on a Level 1 measurement.

The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

There were no Level 3 items for the six-month periods ended February 28, 2018 and 2017.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

6 Months Ended

Feb. 28, 2018

Marketable Securities [Abstract]

MARKETABLE SECURITIES

NOTE 4 - MARKETABLE SECURITIES:

The Company's marketable securities include investments in equity securities of D.N.A and in held to maturity bonds.

Composition:


	February 28, 2018		August 31, 2017
Short-term:
D.N.A (see b below)	$	908	$	996
Held to maturity bonds (see c below)		2,321		1,864
	$	3,229	$	2,860
Long-term:
Held to maturity bonds (see c below)	$	3,306	$	2,151

D.N.A

The investment in D.N.A is reported at fair value, with unrealized gains and losses, recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.

The D.N.A ordinary shares are traded on the Tel Aviv Stock Exchange. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

As of February 28, 2018, the Company owns approximately 6.9% of D.N.A’s outstanding ordinary shares.

The cost of the securities as of February 28, 2018 and August 31, 2017 is $595.

Held to maturity securities

The amortized cost and estimated fair value of held-to-maturity securities as of February 28, 2018, are as follows:

	February 28, 2018
	Amortized cost		Gross unrealized losses			Estimated fair value
Short-term:
Commercial bonds	$	2,284	$	(11	)	$	2,273
Accrued interest		37		-			37

Long-term		3,306		(42	)		3,264
	$	5,627	$	(53	)	$	5,574

As of February 28, 2018, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $3,306, and the yield to maturity rates vary between 1.40% to 1.90%.

The amortized cost and estimated fair value of held-to-maturity securities as of August 31, 2017, are as follows:

	August 31, 2017
	Amortized cost		Gross unrealized losses			Estimated fair value
Short-term:
Commercial bonds	$	1,823	$	(1	)	$	1,822
Accrued interest		41		-			41

Long-term		2,151		-			2,151
	$	4,015	$	(1	)	$	4,014

As of August 31, 2017, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $2,151 and the yield to maturity rates vary between 1.30% to 1.87%.

Held to maturity securities which will mature during the 12 months from the balance sheet date are included in short-term marketable securities. Held to maturity securities with maturity dates of more than one year are considered long-term marketable securities.

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Feb. 28, 2018
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 5 - STOCKHOLDERS’ EQUITY: On April 2, 2015, the Company entered into an At The Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc., as successor to FBR Capital Markets & Co. (“FBR”), as amended, pursuant to which the Company may, from time to time and at its option, issue and sell shares of its common stock having an aggregate offering price of up to $25,000 through FBR as its sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to the Company’s effective shelf registration statement on Form S-3 including a prospectus dated February 2, 2017, as supplemented by a prospectus supplement dated April 5, 2017. The Company will pay FBR a commission of 3.0% of the gross proceeds of the sale of any shares sold through FBR. Through February 28, 2018, 535,771 shares were sold under the Sales Agreement for aggregate net proceeds of $4,906 and an additional 35,001 shares were subsequently sold during March 2018 for aggregate net proceeds of $243.

Related Parties - Transactions	6 Months Ended
Related Parties - Transactions	Feb. 28, 2018
Related Parties - Transactions [Abstract]
RELATED PARTIES - TRANSACTIONS	NOTE 6 - RELATED PARTIES - TRANSACTIONS: On July 1, 2008, the Subsidiary entered into two consulting agreements with KNRY Ltd. (“KNRY”), an Israeli company owned by the Chief Scientific Officer (the "CSO"), whereby the Chief Executive Officer (the "CEO") and the CSO, through KNRY, provide services to the Company (the “Consulting Agreements”). The Consulting Agreements are both terminable by either party upon 140 days prior written notice. The Consulting Agreements, as amended, provide that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements and that the monthly consulting fee paid to the CEO and the CSO is NIS 127,570 ($37) and NIS 80,454 ($23), respectively. In addition to the Consulting Agreement, based on a relocation cost analysis prepared by consulting company ORI - Organizational Resources International Ltd., the Company pays for certain direct costs and expenses incurred in connection with the relocation of the CEO to New York, up to an aggregate yearly amount of $365 in addition to any double taxation.

Taxes on Income	6 Months Ended
Taxes on Income	Feb. 28, 2018
Taxes on Income [Abstract]
TAXES ON INCOME	NOTE 7 - TAXES ON INCOME: On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (the "TCJA"), which among other changes reduces the federal corporate tax rate to 21%. Deferred taxes are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The reduction of the tax rate and TCJA had no impact on the net deferred taxes of the Company.

Significant Accounting Policies (Policies)

6 Months Ended

Feb. 28, 2018

Significant Accounting Policies [Abstract]

General

a.	General:

Incorporation and operations

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

The License Agreement shall remain in effect until the expiration of the Royalty Term. The License Agreement contains customary termination provisions.

The following table sets forth the transactions in deferred revenues balances for the six-month period ended February 28, 2018 and the year ended August 31, 2017:

	Six months ended February 28,			Year ended August 31,
	2018			2017

Deferred revenue at the beginning of period	$	16,286		$	14,766
Amounts received		-			4,000
Amounts due to the Company		-			(24	)
Revenue recognized		(1,215	)		(2,456	)
Deferred revenue at the end of period		15,071			16,286
Less – current deferred revenue portion		(2,449	)		(2,449	)
Non-current deferred revenue portion	$	12,622		$	13,837

Development and liquidity risks

Loss per common share

Loss per common share

Condensed Consolidated Financial Statements Preparation

Condensed Consolidated Financial Statements Preparation

Newly issued and recently adopted Accounting Pronouncements

Newly issued and recently adopted Accounting Pronouncements

Significant Accounting Policies (Tables)

6 Months Ended

Feb. 28, 2018

Significant Accounting Policies [Abstract]

Summary of transactions in deferred revenues

	Six months ended February 28,			Year ended August 31,
	2018			2017

Deferred revenue at the beginning of period	$	16,286		$	14,766
Amounts received		-			4,000
Amounts due to the Company		-			(24	)
Revenue recognized		(1,215	)		(2,456	)
Deferred revenue at the end of period		15,071			16,286
Less – current deferred revenue portion		(2,449	)		(2,449	)
Non-current deferred revenue portion	$	12,622		$	13,837

Marketable Securities (Tables)

6 Months Ended

Feb. 28, 2018

Marketable Securities [Abstract]

Schedule of marketable securities include investments in equity securities

	February 28, 2018		August 31, 2017
Short-term:
D.N.A (see b below)	$	908	$	996
Held to maturity bonds (see c below)		2,321		1,864
	$	3,229	$	2,860
Long-term:
Held to maturity bonds (see c below)	$	3,306	$	2,151

Schedule of amortized cost and estimated fair value of held-to-maturity securities

	February 28, 2018
	Amortized cost		Gross unrealized losses			Estimated fair value
Short-term:
Commercial bonds	$	2,284	$	(11	)	$	2,273
Accrued interest		37		-			37

Long-term		3,306		(42	)		3,264
	$	5,627	$	(53	)	$	5,574

	August 31, 2017
	Amortized cost		Gross unrealized losses			Estimated fair value
Short-term:
Commercial bonds	$	1,823	$	(1	)	$	1,822
Accrued interest		41		-			41

Long-term		2,151		-			2,151
	$	4,015	$	(1	)	$	4,014

- Definition

Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.

+ References + Details

Significant Accounting Policies (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Significant Accounting Policies [Abstract]
Deferred revenue at the beginning of period	$ 16,286	$ 14,766
Amounts received		4,000
Amounts due to the Company		(24)
Revenue recognized	(1,215)	(2,456)
Deferred revenue at the end of period	15,071	16,286
Less - current deferred revenue portion	(2,449)	(2,449)
Non-current deferred revenue portion	$ 12,622	$ 13,837

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
	Nov. 30, 2015	Feb. 28, 2018	Feb. 28, 2017	Feb. 28, 2018	Feb. 28, 2017	Aug. 31, 2017
Significant Accounting Policies (Textual)
Recognize revenue				$ 1,215		$ 2,456
Securities excluded from the calculation of diluted net loss		1,388,122	1,631,174	1,406,175	2,053,153
License Agreement [Member]
Significant Accounting Policies (Textual)
License agreement value				$ 19,383
Recognize revenue				4,312
Deferred revenue		$ 15,071		$ 15,071
HTIT [Member]
Significant Accounting Policies (Textual)
Percentages of royalties on net sales				10.00%
Aggregate license costs				$ 37,500
License costs payable		3,000		3,000
Amount paid subject to the Company entering into certain agreements		8,000		8,000
Payable upon achievement of certain milestones and conditions		$ 26,500		$ 26,500
Royalty commitment description				In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company's patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.
Royalty term				15 years
HTIT [Member] \| Stock Purchase Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued	1,155,367
Number of common stock issued ,value	$ 12,000

Commitments (Details) $ in Thousands									1 Months Ended					6 Months Ended
Commitments (Details) $ in Thousands	Jun. 05, 2017 USD ($)	May 03, 2017 shares	Oct. 01, 2016	Jun. 13, 2016 USD ($)	Jun. 13, 2016 EUR (€)	May 11, 2016 USD ($)	Mar. 03, 2016 USD ($)	Mar. 03, 2016 CHF (SFr)	Feb. 14, 2018 USD ($)	Dec. 18, 2017 USD ($)	Feb. 21, 2017 USD ($)	Jul. 24, 2016 USD ($)	Mar. 31, 2011 USD ($) shares	Feb. 28, 2018 USD ($) shares	Feb. 28, 2018 CHF (SFr) shares	Feb. 28, 2018 EUR (€) shares	Feb. 15, 2011
Commitments (Textual)
Commitments for consulting services											$ 952
Expense which was recognized														$ 786
Office Building [Member]
Commitments (Textual)
Operating lease, term			60 months
Lessee, description														The annual lease payment is New Israeli Shekel ("NIS") 119,000 ($34) from October 2016 through September 2018 and NIS 132,000 ($38) from October 2018 through September 2021, and is linked to the increase in the Israeli consumer price index ("CPI") (as of February 28, 2018, the future lease payments until the expiration of the lease agreement will be $134, based on the exchange rate as of February 28, 2018).	The annual lease payment is New Israeli Shekel ("NIS") 119,000 ($34) from October 2016 through September 2018 and NIS 132,000 ($38) from October 2018 through September 2021, and is linked to the increase in the Israeli consumer price index ("CPI") (as of February 28, 2018, the future lease payments until the expiration of the lease agreement will be $134, based on the exchange rate as of February 28, 2018).	The annual lease payment is New Israeli Shekel ("NIS") 119,000 ($34) from October 2016 through September 2018 and NIS 132,000 ($38) from October 2018 through September 2021, and is linked to the increase in the Israeli consumer price index ("CPI") (as of February 28, 2018, the future lease payments until the expiration of the lease agreement will be $134, based on the exchange rate as of February 28, 2018).
Bio Jerusalem [Member]
Commitments (Textual)
Royalty percentage														4.00%
Royalty percentage maximum percentage of grants received														100.00%	100.00%	100.00%
Grants received														$ 65
Israel Innovation Authority [Member]
Commitments (Textual)
Royalty percentage														3.50%
Total grants received														$ 2,194
Israel Innovation Authority [Member] \| Minimum [Member]
Commitments (Textual)
Royalty percentage														100.00%
Israel Innovation Authority [Member] \| Maximum [Member]
Commitments (Textual)
Royalty percentage														150.00%
Entera Bio Ltd. [Member] \| D.N.A. [Member]
Commitments (Textual)
Ownership percentage retained													3.00%
Ordinary shares received \| shares													4,202,334
Royalty percentage													3.00%				8.00%
Cost method investment													$ 1
Advisor [Member]
Commitments (Textual)
Commitments for consulting services	$ 958
Expense which was recognized														$ 160
Shares issued for services \| shares		10,000												7,500	7,500	7,500
Fair value of the shares issued														$ 64
Clinical Research Organization Service Agreement [Member]
Commitments (Textual)
Commitments for consulting services									$ 7,030
Expense which was recognized														547
First Master Service Agreement [Member]
Commitments (Textual)
Commitments for consulting services						$ 1,283
Expense which was recognized														1,275
Master Service Agreement [Member]
Commitments (Textual)
Commitments for service agreement				$ 2,780	€ 2,360,000
Expense which was recognized														1,347		€ 1,187,390
Term of agreement				4 years	4 years
General Technical Agreement [Member]
Commitments (Textual)
Expense which was recognized														3,989
Commitments for service agreement												$ 4,300
Vendor [Member]
Commitments (Textual)
Expense which was recognized														675	SFr 665,000
Development and production on capsules							$ 1,061	SFr 1,000,000
Vendor One [Member]
Commitments (Textual)
Expense which was recognized														$ 109
Commitments for service agreement										$ 2,905

Marketable Securities (Details) - USD ($) $ in Thousands	Feb. 28, 2018	Aug. 31, 2017
Short-term:
D.N.A (see b below)	$ 908	$ 996
Held to maturity bonds (see c below)	2,321	1,864
Marketable securities	3,229	2,860
Long-term:
Held to maturity bonds (see c below)	$ 3,306	$ 2,151

Marketable Securities (Details 1) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
Marketable Securities (Details 1) - USD ($) $ in Thousands	Feb. 28, 2018	Aug. 31, 2017
Summary of held to maturity securities [Abstract]
Amortized cost	$ 5,627	$ 4,015
Gross unrealized losses	(53)	(1)
Estimated fair value	5,574	4,014
Short-term [Member] \| Commercial bonds [Member]
Summary of held to maturity securities [Abstract]
Amortized cost	2,284	1,823
Gross unrealized losses	(11)	(1)
Estimated fair value	2,273	1,822
Short-term [Member] \| Accrued interest [Member]
Summary of held to maturity securities [Abstract]
Amortized cost	37	41
Gross unrealized losses
Estimated fair value	37	41
Long-term [Member]
Summary of held to maturity securities [Abstract]
Amortized cost	3,306	2,151
Gross unrealized losses	(42)
Estimated fair value	$ 3,264	$ 2,151

Marketable Securities (Details Textual) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Marketable Securities (Textual)
Percentage of ownership interest	6.90%
Cost of securities	$ 595	$ 595
Marketable securities	$ 3,306	$ 2,151
Marketable securities maturity dates, description	After one year through two years.	After one year through two years.
Marketable securities maturity, term	12 months
Minimum [Member]
Marketable Securities (Textual)
Yield to cost rates	1.40%	1.30%
Maximum [Member]
Marketable Securities (Textual)
Yield to cost rates	1.90%	1.87%

Stockholders' Equity (Details) - Sales Agreement [Member] - USD ($) $ in Thousands			6 Months Ended
	Mar. 31, 2018	Apr. 02, 2015	Feb. 28, 2018
Stockholders' Equity (Textual)
Common stock offering price		$ 25,000
Percentage of commission		3.00%
Number of shares sold			535,771
Net proceeds from offering			$ 4,906
Subsequent Event [Member]
Stockholders' Equity (Textual)
Number of shares sold	35,001
Net proceeds from offering	$ 243

Related Parties - Transactions (Details) $ in Thousands		6 Months Ended
Related Parties - Transactions (Details) $ in Thousands	Jul. 01, 2008 Agreements	Feb. 28, 2018 USD ($)	Feb. 28, 2018 ILS (₪)
KNRY [Member]
Related Parties Transactions (Textual)
Number of agreements \| Agreements	2
Consulting agreements, description	The Consulting Agreements are both terminable by either party upon 140 days prior written notice.
CEO [Member]
Related Parties Transactions (Textual)
Consulting fee		$ 37	₪ 127,570
CSO [Member]
Related Parties Transactions (Textual)
Consulting fee		23	₪ 80,454
New York [Member] \| Relocation of CEO [Member]
Related Parties Transactions (Textual)
Relocation cost \| $		$ 365

Taxes on Income (Details)	1 Months Ended
Taxes on Income (Details)	Dec. 22, 2017
Taxes on Income (Textual)
Federal corporate tax rate, reduced	21.00%